María Ángeles Meléndez Carmona

Dr. María Ángeles Meléndez Carmona

Hospital Universitario 12 De Octubre, Madrid, Spain
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2019 in International Journal of Antimicrobial Agents
Verified
Journal Article
Closed access
MCMaría Ángeles Meléndez Carmona
María Ángeles Meléndez Carmona
IMIrene Muñoz-Gallego
Irene Muñoz-Gallego
EVEsther Viedma
Esther Viedma
Jaime Lora-TamayoJaime Lora-Tamayo
Jaime Lora-Tamayo
FCFernando Chaves
Fernando Chaves

23 March 2024 in Antibiotics
Verified
Journal Article
Open access
PDF file
Jaime Lora-TamayoJaime Lora-Tamayo
Jaime Lora-Tamayo
MMMikel Mancheño-Losa
Mikel Mancheño-Losa
MCMaría Ángeles Meléndez Carmona
María Ángeles Meléndez Carmona
PHPilar Hernández-Jiménez
Pilar Hernández-Jiménez
Natividad BenitoNatividad Benito
Natividad Benito
Óscar MurilloÓscar Murillo
Óscar Murillo
Prosthetic joint infections are considered difficult to treat they needing aggressive surgery and long antimicrobial treatments. However, the exact duration of these therapies has been established empirically. In the last years, several studies have explored the possibility of reducing the length of treatment in this setting, with conflicting results. In this narrative review, we critically appraise the published evidence, considering the different surgical approaches (implant retention [DAIR] and one-step and two-step exchange procedures) separately. In patients managed with DAIR, usually treated for at least 12 weeks, a large, randomized trial failed to show that 6 weeks were non-inferior. However, another randomized clinical trial supports the use of 8 weeks, as long as the surgical conditions are favorable and antibiotics with good antibiofilm activity can be administered. In patients managed with a two-step exchange procedure, usually treated during 6 weeks, a randomized clinical trial showed the efficacy of a 4-week course of antimicrobials. Also, the use of local antibiotics may allow the use of even shorter treatments. Finally, in the case of one-step exchange procedures, there is a trend towards reducing the length of therapy, and the largest randomized clinical trial supports the use of 6 weeks of therapy.

18 August 2022 in Antibiotics
Verified
Journal Article
Open access
PDF file
IMIrene Muñoz-Gallego
Irene Muñoz-Gallego
MCMaría Ángeles Meléndez Carmona
María Ángeles Meléndez Carmona
Jaime Lora-TamayoJaime Lora-Tamayo
Jaime Lora-Tamayo
CGCarlos Garrido-Allepuz
Carlos Garrido-Allepuz
FCFernando Chaves
Fernando Chaves
EVEsther Viedma
Esther Viedma
Background: Persistent and relapsing prosthetic joint infection (PJI) due to Staphylococcus aureus presents a clinical challenge. This study aimed to provide an extensive description of phenotypic and genomic changes that could be related to persistence or relapse. Methods: Initial and second S. aureus isolates from 6 cases of persistent and relapsing PJI, along with clinical isolates from 8 cases, with favorable outcome were included. All isolates were studied by phenotypic and genotypic approaches. Results: Recurrent S. aureus isolates exhibited a significant increase in adhesive capacity, invasion and persistence compared to resolved isolates. No association was found for the presence or absence of certain genes with the persistence or relapse of PJI. All sequential isolates showed identical sequence type (ST). Resistance gene loss during the infection and a great diversity of variants in different virulence genes between the pair of strains, mainly in genes encoding adhesins such as fnbA, were observed. Conclusions: S. aureus-caused relapse and persistence PJI is associated with bacterial phenotypical and genotypical adaptation. The main paths of adaptation were persistence in the intracellular compartment, and the loss of antibiotic resistance genes and variant acquisition, especially in genes encoding adhesins.

19 September 2022 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Closed access
PDF file
MCMaría Ángeles Meléndez Carmona
María Ángeles Meléndez Carmona
MMMikel Mancheño-Losa
Mikel Mancheño-Losa
ARAlbert Ruiz-Sorribas
Albert Ruiz-Sorribas
IMIrene Muñoz-Gallego
Irene Muñoz-Gallego
EVEsther Viedma
Esther Viedma
Jaime Lora-TamayoJaime Lora-Tamayo
Jaime Lora-Tamayo
Levofloxacin and rifampicin are the preferred treatment for prosthetic joint infection (PJI) caused by Staphylococcus aureus, especially when managed with implant retention (DAIR). However, a significant variability of success has been reported, which could be related to intrinsic characteristics of the microorganism. Our aim was to evaluate the variability in the anti-biofilm response to levofloxacin and rifampicin in a clinical collection of S. aureus. Eleven levofloxacin- and rifampicin-susceptible S. aureus isolates causing PJI managed with DAIR were included. Levofloxacin, rifampicin and levofloxacin + rifampicin were tested in an in vitro static biofilm model in microtitre plates, where 48 h biofilms were challenged with antimicrobials during 24 h. Additionally, two genetically similar strains were tested in the CDC Biofilm Reactor, where 48 h biofilms were treated during 56 h. Antimicrobial activity was assessed by viable biofilm-embedded cells recount, and by crystal violet staining. All antimicrobial regimens showed significant anti-biofilm activity, but a notable scattering in the response was observed across all strains (inter-strain coefficient of variation for levofloxacin, rifampicin and levofloxacin + rifampicin of 22.8%, 35.8% and 34.5%, respectively). This variability was tempered with the combination regimen when tested in the biofilm reactor. No correlation was observed between the minimal biofilm eradicative concentration and the antimicrobial activity. Recurrent S. aureus isolates exhibited higher biofilm-forming ability compared with strains from resolved infections (7.6 log10 cfu/cm2±0.50 versus 9.0 log10 cfu±0.07). Significant variability may be expected in response to levofloxacin and rifampicin among biofilm-embedded S. aureus. A response in the lower range, together with other factors of bad prognosis, could be responsible of treatment failure.

5 April 2025 in Antibiotics
Verified
Journal Article
Open access
PDF file
MMMikel Mancheño-Losa
Mikel Mancheño-Losa
MCMaría Ángeles Meléndez Carmona
María Ángeles Meléndez Carmona
CLCarlos Lumbreras
Carlos Lumbreras
Jaime Lora-TamayoJaime Lora-Tamayo
Jaime Lora-Tamayo
Background: The presence of biofilms and low antimicrobial concentrations in bone tissue make prosthetic joint infections (PJI) difficult to treat. Ceftobiprole (CTO) has a potential role in MRSA PJI. This study evaluated the efficacy of ceftobiprole and daptomycin (DAP) alone and in combination against MRSA biofilms at expected bone tissue concentrations. We assessed whether CTO-DAP outperformed DAP combined with a non-anti-MRSA beta-lactam (cefazolin [CZO]). Methods: A dynamic in vitro PK/PD biofilm model (CDC biofilm reactor) was used to simulate concentrations expected in cortical bone at a standard dosing of DAP (10 mg/kg/24 h), CTO (500 mg/8 h), and CZO (2 g/8 h), and assess performance against a 48-h MRSA biofilm from two clinical isolates that cause PJI (MRSA-1811 and MRSA-1733). Time–kill curves using the log change method (Δlog10 CFU/cm2) assessed antimicrobial efficacy over 56 h. Resistance emergence was monitored. Results: Although both monotherapies were active, neither reached bactericidal levels nor was one superior to the other (Δlog10 CFU/cm2 CTO vs. DAP: −1.44 ± 0.25 vs. −1.50 ± 0.01 [p = 0.686] and −1.55 ± 0.74 vs. −0.56 ± 0.36 [p = 0.108] for MRSA-1811 and MRSA-1733, respectively). Only in the MRSA-1811 isolate did the CTO-DAP combination improve the activity of each monotherapy, without achieving a synergistic effect (Δlog10 CFU/cm2: CTO-DAP −2.087 ± 0.048 vs. CTO −1.436 ± 0.249 [p = 0.013] and vs. DAP −1.503 ± 0.011 [p = 0.006]). No combination therapy (CTO-DAP vs. DAP-CZO) outperformed the other in either strain. No resistant bacterial subpopulations appeared with any antibiotic regimen. Conclusions: At clinically relevant concentrations, ceftobiprole and daptomycin showed similar activity against MRSA biofilms. The CTO-DAP combination showed comparable efficacy to DAP-CZO.

10 January 2026 in Virulence
Verified
Journal Article
Open access
MCMaría Ángeles Meléndez Carmona
María Ángeles Meléndez Carmona
MMM. Carmen Martín-Higuera
M. Carmen Martín-Higuera
RRRaúl Recio
Raúl Recio
EBEva Benavent
Eva Benavent
JGJoan Gómez-Junyent
Joan Gómez-Junyent
JLJaime Lora-Tamayo
Jaime Lora-Tamayo
Escherichia coli is a key pathogen in extraintestinal infections, including prosthetic joint infections (PJIs), which account for approximately 9% of all such cases. Despite its clinical relevance, the molecular pathogenesis of E. coli in PJIs remains poorly defined. This study investigated the clinical, phylogenetic, and virulence profiles of E. coli isolates from PJIs and compared them to isolates from bacteremic urinary tract infections (UTIs). A total of 13 isolates from each infection type were analyzed using whole-genome sequencing (WGS) to determine phylogenetic relationships, sequence types, and the presence of virulence genes. PJI isolates exhibited substantial genetic diversity, encompassing 10 sequence types, with ST131 and ST69 being the most frequent. Phylogroup B2 predominated (53.9%) among PJI isolates. Adhesion and biofilm-related genes, such as fimG/H, csg, and epaO, were highly prevalent in PJI isolates, supporting the role of biofilm formation in pathogenesis. Conversely, toxin-associated genes (e.g. pic and senB) were more frequently detected in UTI isolates. Notably, the matA gene, linked to biofilm enhancement, was significantly associated with microbiological failure in PJIs (75% vs. 0%, p = 0.02). Phylogenetic analyses revealed no clustering by infection type, suggesting that ExPEC strains share a versatile genomic background, enabling them to adapt to different infection environments. The study highlights the critical role of biofilm formation in PJIs and underscores the genetic adaptability of ExPEC strains, which lack distinct virulence profiles specific to PJIs. However, the small number of PJI isolates limits the generalizability of these findings and warrants confirmation in larger cohorts.